Pharmacological properties of the new fixed dose combination of aclidinium bromide and formoterol

Abstract

The new fixed dose combination of aclidinium bromide and formoterol fumarate represents a rationally based approach to COPD treatment satisfying both local and international recommendations. Pharmacological properties of formoterol are well known so the present text focuses on the pharmacology of aclidinium bromide and synergism of both substances.

Keywords

• COPD
• aclidinium bromide
• formoterol